[Pharmacokinetic and clinical evaluations of micronomicin by intravenous drip infusion].
The safety and pharmacokinetics of micronomicin (MCR) by intravenous drip infusion were evaluated and the intravenous drip infusion of MCR was carried out on several cases on which the blood levels and clinical usefulness of MCR were investigated. Five healthy adult male volunteers received by crossover method 1 hour intravenous drip infusion of MCR in doses of 60 and 120 mg and intramuscular injection in a dose of 120 mg. The mean highest serum level was 6.3 micrograms/ml by intravenous drip infusion of 60 mg, 10.7 micrograms/ml by intravenous drip infusion of 120 mg, and 10.3 micrograms/ml by intramuscular injection of 120 mg. Serum levels of MCR were similar for intravenous drip infusion and intramuscular injection of 120 mg of MCR. The biological serum half-lives of MCR were 2.15 hours by 1 hour intravenous drip infusion of 60 mg, 2.54 hours by 1 hour intravenous drip infusion of 120 mg, and 1.59 hours by intramuscular injection of 120 mg. The mean urinary recovery rates within 24 hours after administration were 74.3% by 1 hour intravenous drip infusion of 60 mg, 59.6% by 1 hour intravenous drip infusion of 120 mg, and 64.9% by intramuscular injection of 120 mg, the results being nearly consistent. In all treatment groups, MCR could be safely administered. Intravenous drip infusion of MCR in a dose of 60 or 120 mg once or twice a day was conducted on a total of 6 cases consisting of 2 cases of pneumonia and 4 cases of urinary tract infections.(ABSTRACT TRUNCATED AT 250 WORDS)